Ask AI
Risk Factors for Progression in PBC

CE / CME

Identifying Risk Factors for Disease Progression and Poor Response in PBC: Implications for First-line Therapy

Pharmacists: 0.75 contact hour (0.075 CEUs)

Physicians: maximum of 0.75 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.75 Nursing contact hour

Released: March 30, 2026

Expiration: March 29, 2027

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Sonal Kumar, MD, MPH, discusses how to identify patients with primary biliary cholangitis (PBC) who are at greatest risk for severe outcomes, when and how to assess responses to first-line therapy, and how to integrate baseline risk factors into evaluation of the response to first-line therapy.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with PBC do you provide care for in a typical month?

For those who practice in academic or community settings, please indicate your practice setting:

If you practice in gastroenterology, is hepatology your specialty?

A 44-year-old woman newly diagnosed with PBC has a liver stiffness measure of 13 kPa and an alkaline phosphatase (ALP) of 4 times the upper limit of normal (ULN). She is started on ursodeoxycholic acid (UDCA) at a dose of 13-15 mg/kg/day. Based on her risk factors, how many months after starting UDCA would you recommend her response first be assessed?

I know how to personalize the management of PBC based on a person’s individual risk for disease progression.